WHWK

Whitehawk Therapeutics Inc NASDAQ Listed Aug 1, 2017

Healthcare ·Biotechnology ·US · ir.whitehawktx.com

$4.15

After hrs $4.15 +0.00%

Mkt Cap $205.1M

52w Low $1.55 88.7% of range 52w High $4.48

50d MA $3.74 200d MA $2.62

P/E (TTM) -12.1x

EV/EBITDA -1.0x

P/B 1.8x

Debt/Equity 0.0x

ROE -15.1%

P/FCF -1.5x

RSI (14) —

ATR (14) —

Beta 0.62

50d MA $3.74

200d MA $2.62

Avg Volume 185.1K

About

Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	-0.55	-0.34	+38.2%	3.90	+0.3%	+0.3%	+0.0%	+1.3%	-2.3%	-7.9%	—
Nov 6, 2025	AMC	-0.51	-0.26	+49.0%	2.10	+0.0%	-1.4%	+3.8%	+6.2%	+6.2%	-0.5%	—
Aug 7, 2025	AMC	0.49	-0.76	-255.1%	1.72	+0.0%	+1.7%	-1.7%	-0.6%	-0.6%	-5.8%	—
May 8, 2025	AMC	-0.46	-0.36	+21.7%	1.64	+6.1%	+3.7%	+1.8%	+0.6%	+2.4%	+3.0%	—
Mar 18, 2025	AMC	-0.22	-0.67	-204.5%	2.05	-13.7%	-1.5%	-4.4%	+0.0%	-3.4%	-4.9%	—

Recent Filings

8-K

Unknown — 8-K Filing

Whitehawk's rebranding and focus on next-generation ADC cancer treatments signal strategic repositioning; investors should monitor clinical progress and capital runway, as clinical-stage biotech success depends on trial outcomes and funding availability.

Mar 12

Data updated apr 27, 2026 9:21am · Source: massive.com